Fitzpatrick Skin Type and Laser Tattoo Removal

The same laser light that fragments tattoo ink also heats melanin in the skin above it. Darker skin means more melanin in the path of the beam, and the competition between two absorption targets, the ink and the pigment that gives your skin its color, is the whole reason your skin type matters for laser tattoo removal. A system designed in 1975 for a completely different clinical problem, the Fitzpatrick scale, is what every clinician will use to talk about where you fall on that spectrum and what it means for your candidacy, your laser settings, your session count, and your risk of pigment changes afterward.

This article gives you the physics, the real numbers from peer-reviewed literature, and the practical list of questions to bring to a consultation. It does not tell you whether to pursue removal. That decision belongs at the consultation, because your Fitzpatrick type is one piece of a larger clinical picture only a clinician can assess in person.

What the Fitzpatrick scale actually is

Thomas B. Fitzpatrick, a dermatologist at Harvard, published the scale in 1975. Its purpose was not tattoo removal. The scale was built to dose ultraviolet light for psoralen-plus-UVA (PUVA) therapy, a treatment for psoriasis and other skin conditions. The original version had four types, calibrated on a question about how a patient’s skin reacts to 45 to 60 minutes of noon summer sun: does it burn, tan, or some combination. Types V and VI, covering brown and deeply pigmented dark brown to black skin, were added in 1988 because the original four types effectively omitted the majority of the world’s population (Fitzpatrick scale, Wikipedia summary; StatPearls entry on laser Fitzpatrick recommendations).

The short descriptions, roughly:

• Type I: Always burns, never tans. Pale white skin, often with freckles, red or light blond hair, blue or green eyes.
• Type II: Usually burns, tans minimally. Fair skin, blond or red-brown hair, blue, green, or hazel eyes.
• Type III: Sometimes mild burn, gradually tans to light brown. Medium white to olive skin, dark blond to brown hair.
• Type IV: Burns minimally, always tans to moderate brown. Olive or light brown skin; common in Mediterranean, Hispanic, Middle Eastern, and some Asian populations.
• Type V: Rarely burns, tans to dark brown. Brown skin; common in Middle Eastern, South Asian, and some African populations.
• Type VI: Never burns, tans to deep brown or black. Deeply pigmented dark brown to black skin.

The clinical variable the scale actually measures is how much melanin (the pigment that gives skin its color) is present in the epidermis (the outer skin layer), and how reactive the skin’s inflammation-and-pigment response is to stimulus. That variable turns out to govern laser tattoo removal risk almost as directly as it governs UVR sensitivity, which is why the scale migrated from PUVA dosing into laser medicine. It is a useful shorthand for a real clinical variable. It was not designed for laser tattoo removal, and the fit is approximate rather than exact.

Where you fall on the scale, roughly

You can get close to your Fitzpatrick type by answering the UVR-response questions the clinician would ask. The problem is that self-assessment is a systematically different process than provider assessment, and the two do not produce the same answers.

A 2024 study published in the Journal of Clinical and Aesthetic Dermatology compared self-reported Fitzpatrick type against provider-assigned Fitzpatrick type across 472 patients. Patients tended to report both more burning and more tanning than the provider assessed, with a mean difference of about half a Fitzpatrick point. The authors concluded that the scale should be used with “extreme caution to prevent the misuse and overgeneralization” of self-assessment and that provider examination and patient interview together produce more accurate classifications than either alone (Bhanot et al. 2024, JCAD).

The StatPearls entry on laser Fitzpatrick recommendations is blunter about where self-assessment fails worst. The scale correlates reasonably with sun sensitivity in non-Hispanic white and Hispanic populations, but the correlation breaks down in Black participants, where self-reports of burning and tanning patterns do not map onto the UVR-response framework the scale was built on (StatPearls, NCBI Bookshelf NBK557626). The scale was extended to include types V and VI in 1988, but the underlying questions were not redesigned for skin that never burns and always tans deeply, and that gap shows up in the self-report accuracy data.

What this means practically. A home Fitzpatrick quiz gets you in the ballpark, and that is genuinely useful. It does not replace a provider’s visual examination and targeted history. If you land between II and III on a home quiz, your clinician may assign you III. If you land at V on a home quiz, your clinician may assign you IV or VI based on factors a visual exam catches that a quiz does not. Knowing the ballpark is enough to orient yourself for the conversation. The clinician will assign the number that actually drives your fluence and wavelength choices.

Why melanin changes the physics of laser tattoo removal

Selective photothermolysis, the framework that governs every modern laser in dermatology, was laid out by Anderson and Parrish in Science in 1983 (Anderson and Parrish 1983). The idea is simple. Aim a laser at a specific wavelength of light that a target pigment absorbs strongly. Use a pulse short enough that the pigment heats, expands, and fragments before the heat diffuses into surrounding tissue. The surrounding tissue stays intact. The pigment does not.

For tattoo removal, the target is ink. The problem for darker skin is that melanin in the epidermis is also a pigment, and it absorbs light across much of the same wavelength range the laser is trying to use on the ink underneath. Any photon absorbed by epidermal melanin is a photon that did not reach the ink, and it is a photon that heated melanocytes (the skin cells that produce melanin) instead. The more melanin in the epidermis, the more competition for the laser’s energy, and the more collateral heat the epidermis receives per pulse.

How much melanin competes depends on the laser’s wavelength. Melanin absorbs shorter wavelengths heavily and longer wavelengths much less. The four wavelengths you will encounter in standard tattoo-removal clinics line up roughly like this:

Risk-profile column draws on the Ho and Goh 2015 review cited below.

Ho and Goh’s 2015 clinical update in the Journal of Cutaneous and Aesthetic Surgery states the recommendation directly: “In darker skin types where there is heavy epidermal melanin content, QS Nd:YAG laser is the laser of choice to reduce the risks of post-inflammatory hyper- and hypopigmentation post tattoo removal.” Their review of historical hypopigmentation rates across Q-switched wavelengths in darker skin makes the physics visible: ruby at 694 nm produced hypopigmentation in 38% of cases, alexandrite at 755 nm in 2%, and Nd:YAG at 1064 nm in effectively 0% of the populations surveyed (Ho and Goh 2015).

The 1064 nm preference for Fitzpatrick IV-VI is a physical consequence of this absorption gap. Longer wavelength, less melanin competition, more energy reaching the dermis where the ink is, less thermal load on the epidermis. It is also the only wavelength that treats solid black tattoos directly, which covers most tattoos that first-timers are researching removal for. If a clinic’s only device is a 532 nm Q-switched laser and your Fitzpatrick type is V or VI, that is not a clinic for your tattoo. If the clinic has a 1064 nm device, that is the wavelength your treatment will center on, and the 532 nm component will be used cautiously, at reduced energy, only where colored ink requires it.

Two ways the competition for photons produces complications are worth naming, because the names are how you will talk about them:

Hyperpigmentation. Post-inflammatory hyperpigmentation (PIH) is a darkening of the treated area that shows up weeks after a session and typically fades over months. The mechanism is that laser-induced inflammation signals surviving melanocytes to produce more melanin, producing darker patches on already-pigmented skin. PIH is usually temporary, sometimes lasting a year or longer, and it is the most common pigmentary complication in Fitzpatrick III-VI patients.

Hypopigmentation. Hypopigmentation is a lightening of the treated area, caused by direct destruction of melanocytes from absorbed laser energy. Unlike PIH, hypopigmentation is often persistent and sometimes permanent, because the destroyed melanocytes may not be replaced. It is less common than PIH in 1064 nm treatment, but it is the more serious pigmentary complication when it occurs, because it does not reliably resolve on its own. The /guide/scarring/ guide covers pigmentary complications and other adverse outcomes in more detail.

What the literature actually reports on risk rates

The honest version of the risk picture is more useful than a flattened catch-all. The peer-reviewed literature reports real pigmentary complication rates in Fitzpatrick III through VI patients, and the rates move substantially based on the wavelength, the pulse duration, and the protocol the clinic uses.

A prospective comparison study by Kono and colleagues, published in Laser Therapy in 2020, compared 532 nm and 1064 nm lasers in Q-switched (nanosecond) and picosecond versions on 11 Asian patients. The per-laser rates for post-inflammatory hyperpigmentation: 35.1% for 532 nm nanosecond, 24.3% for 532 nm picosecond, 27.0% for 1064 nm nanosecond, 21.6% for 1064 nm picosecond (Kono et al. 2020). Both the picosecond pulse and the 1064 nm wavelength independently lowered PIH; the combination of the two produced the lowest rate of the four. That is the signal to extract.

A safety-and-efficacy study by Nguyen and colleagues, published in Lasers in Surgery and Medicine in 2021, treated 30 Fitzpatrick III-IV patients with a dual-wavelength 1064 nm and 532 nm picosecond laser across up to six sessions spaced 6 to 8 weeks apart. Of 52 tattoos, 88.5% achieved 75% or greater clearance by session six. The safety profile was strong: only one case of prolonged hypopigmentation across the cohort, and the authors framed the protocol as carrying “minimal risk of long-term adverse events” in Fitzpatrick III-IV skin (Nguyen et al. 2021). A well-run picosecond dual-wavelength protocol on Fitzpatrick III-IV skin is genuinely different from the Kono PIH numbers on 532 nm nanosecond; the range is wide because the protocol and wavelength choices move it.

The Fitzpatrick V-VI evidence is thinner. A small case series by Pincelli and colleagues in 2022 followed three patients with Fitzpatrick IV-VI through Nd:YAG 1064 nm treatment on black tattoos. Two of three showed hypopigmentation the authors attributed to sun exposure, short intervals between sessions, or excessive radiant exposure. No hyperpigmentation was reported. The authors’ own framing, paraphrased directly: for patients with Fitzpatrick IV to VI skin, treatment starts with low radiant exposure and a larger spot size, and intervals between sessions matter as much as any per-session setting (Pincelli et al. 2022). A prospective study by Ismail and colleagues in 2024 treated 20 Middle Eastern patients with Fitzpatrick IV skin using picosecond 1064 nm Nd:YAG across two sessions eight weeks apart. The mean improvement on black tattoos was 61% (standard deviation 24.6%). Transient pain, redness, petechiae, and edema resolved in one to three days; no severe side effects were detected (Ismail et al. 2024).

Two things to carry from this literature. First, the PIH rates on 532 nm in Fitzpatrick III-IV are not small, and they describe real patients in the Kono and Nguyen cohorts. Second, the same cohorts demonstrate that wavelength choice, pulse duration, and protocol discipline move those rates substantially, and the 1064 nm picosecond combination with appropriate spacing produces a different safety profile than 532 nm nanosecond at tight intervals. Fitzpatrick V-VI-specific outcome evidence remains sparse, and the article you are reading cannot fix that gap. A clinician with direct experience treating your skin type is the way around the data thinness, not more reading.

The Kirby-Desai connection and what it says about session count

Every clinic you consult with may reference the Kirby-Desai score, or a calculator built from it. The scale was proposed by Kirby, Desai, Desai, Kartono, and Patel in the Journal of Clinical and Aesthetic Dermatology in 2009 as a structured estimator for how many sessions a tattoo will take. It adds points across six factors: Fitzpatrick skin type (scored 1 through 6, matching the type number), location on the body, ink color, amount of ink, scarring, and layering. The total gives a predicted session-count range that a clinician adjusts based on in-person examination (Kirby et al. 2009).

Higher Fitzpatrick type adds more points to the Kirby-Desai total, which translates to more predicted sessions. The paper’s own explanation for why is worth quoting directly: “The decreased efficacy of laser tattoo removal in patients with higher Fitzpatrick scores occurs because the laser operators use lower laser settings and wait longer between treatment sessions to hopefully minimize unwanted side effects.”

That is a different claim than “dark skin is intrinsically harder to treat.” The protocol a careful clinician runs on Fitzpatrick V or VI skin (reduced fluence per pulse, larger spot size, longer intervals between sessions) produces slower fade per session by design, because the same protocol also produces lower PIH and hypopigmentation risk. The session-count difference is a consequence of treating the skin safely, not a prediction that the treatment will fail. Ismail 2024’s Fitzpatrick IV cohort achieved 61% mean improvement in two sessions. In Pincelli 2022’s three-patient case series, the Fitzpatrick V case reached over 96% clearance after 11 sessions of careful 1064 nm treatment; the other two cases reached lower clearance levels in fewer sessions. A longer course is the cost of the protocol adjustment, and the total-cost math follows the longer arc rather than the per-session rate. A good outcome remains on the table.

The Kirby-Desai score is a structured estimate, not a binding quote. It produces a range, not a number. For any specific reader, the actual session count depends on the clinician’s fluence choices, your skin’s response, ink behavior, and factors no scale captures. Treat it as a starting point for the consultation conversation, not as the answer.

What the clinician adjusts for darker skin types

The clinical moves that keep Fitzpatrick IV-VI treatment safe are the questions you bring to consultation. The moves themselves belong to the clinician. Naming them is how you find out whether the clinic has the experience your skin type needs.

Wavelength selection. The 1064 nm Nd:YAG wavelength is the consensus first choice for Fitzpatrick IV-VI, either Q-switched (nanosecond) or picosecond. 532 nm is used cautiously and only when the ink requires it, usually at reduced fluence and with extra care around spacing. 694 nm ruby and 755 nm alexandrite carry higher melanin competition and are generally avoided in Fitzpatrick V-VI by careful clinicians. Asking which wavelengths a clinic has on its device, and whether 1064 nm is among them, is one of the first useful consultation questions for any Fitzpatrick IV-VI patient.

Fluence reduction. Fluence is the energy the laser delivers per unit area, typically in joules per square centimeter. Clinicians treating darker skin reduce fluence to lower the thermal load on the epidermis. The Ismail 2024 protocol used 4 to 5 J/cm² on Fitzpatrick IV at 1064 nm picosecond. The Pincelli case series used 1.6 to 13 J/cm² depending on stage of treatment and patient tolerance. Exact numbers are clinician territory; the concept you should grasp is “less energy per pulse to protect the skin, more sessions to compensate.”

Larger spot size. The spot size is the diameter of the laser beam at the skin. A larger spot distributes energy over more tissue, reduces the peak thermal injury, and lets the light penetrate deeper because less of it scatters laterally. Pincelli 2022 used spot sizes of 3 to 6.8 mm. Whether the clinic adjusts spot size for your Fitzpatrick type, rather than running every patient at the same small spot, is a useful consultation question; the protocol adjustments above require it.

Longer session intervals. Standard spacing between sessions is 6 to 8 weeks to allow immune clearance of fragmented ink and let any inflammation resolve. For Fitzpatrick IV-VI patients, careful clinicians extend that window so any inflammatory pigment response fully settles before the next session adds to it; the Kirby-Desai paper attributed slower outcomes in higher Fitzpatrick scores partly to operators waiting longer between treatment sessions (Kirby et al. 2009). Pincelli 2022 saw complications in cases with short intervals. The /guide/session-spacing/ guide covers the interval question in more detail. Session timing is not a scheduling convenience; it is a risk-reduction tool.

Test patch. A small patch of skin treated at proposed settings, observed for two to four weeks, before committing to treatment on the full tattoo. Test patches are useful in any skin type and especially appropriate in Fitzpatrick V-VI when the clinician has any uncertainty about fluence tolerance. Whether the clinic offers a test patch before committing to full treatment is a reasonable question to raise; the protocol literature consistently recommends one for Fitzpatrick V-VI.

Sun protection and pre- and post-treatment skin care. Sun-induced melanin surge on top of laser-treated skin sharply elevates PIH risk. Daily broad-spectrum SPF 30 or higher and sun avoidance on the treated area are universal. Some clinicians also use pre- and post-treatment topical agents (hydroquinone, retinoids, azelaic acid) to suppress melanin production; these are prescribing decisions with their own indications and warnings, and belong to a clinician managing your care, not the laser operator alone.

Cooling. Most modern clinics use a forced cold-air cooling device during treatment, which reduces thermal damage to the epidermis and also substantially lowers pain. For Fitzpatrick IV-VI, cooling belongs in the safety margin rather than as a comfort add-on.

What operator experience with your Fitzpatrick type actually looks like

Device brand matters less than operator skill. The same laser in the hands of a clinician experienced with Fitzpatrick V skin produces a different outcome than the same laser used by a clinician who mostly treats Fitzpatrick II. The protocol adjustments above have less margin for error on darker skin, and experience is how that margin gets preserved.

A 2024 case report in the Journal of Clinical Medicine documented a 34-year-old Fitzpatrick VI patient who developed extensive facial and neck dyschromia (mixed hyperpigmentation and hypopigmentation) two months after an 808 nm diode laser hair removal treatment. The authors noted that the pattern of dyspigmentation was still recognizable as the outline of the laser probe used (Veronese et al. 2024, PMC10889290). That case is laser hair removal rather than tattoo removal, and the device wavelength is different. The principle transfers cleanly: a laser treatment on Fitzpatrick VI skin at settings calibrated for lighter skin types produces distinctive, sometimes persistent pigmentary complications. The fix is protocol discipline and operator experience, not a different device.

A useful consultation question is simple and direct. “How many patients with Fitzpatrick V or VI skin have you treated for tattoo removal in the past year, and how does your protocol differ for them compared to lighter skin types?” A clinician who can answer that question concretely, naming wavelength choices, fluence adjustments, and interval changes, is giving you different information than a clinician who answers generically. The answer does not need to be “hundreds of cases” to be a good one. It needs to be specific and grounded, and it needs to match what the peer-reviewed literature suggests the protocol should be. The /guide/how-to-choose-clinic/ guide walks through clinic-evaluation questions in more breadth.

Questions to bring to consultation

The consultation is where your treatment plan gets made. You bring the questions; the clinician makes the plan. The questions below target the variables that matter most for Fitzpatrick IV-VI patients.

• What Fitzpatrick type would you assign me, and what does that mean for your wavelength choice for my specific tattoo?
• What device do you use, and what wavelengths are available on it? Is a 1064 nm Nd:YAG among them?
• What fluence range do you plan to start at for my skin type, and how do you adjust if I respond differently than expected?
• What spot size do you use for my skin type?
• How far apart will you space my sessions, and why?
• Will we do a test patch before committing to treatment on the full tattoo?
• What is your sun protection and pre- and post-treatment skin care protocol?
• How many patients with my Fitzpatrick type have you treated for tattoo removal in the past year, and what does your protocol look like for them that is different from lighter-skinned patients?
• If I develop hyperpigmentation or hypopigmentation after a session, what is your response plan, and at what point do you pause treatment?
• What is your honest estimate of my session count range, and how firm is that estimate?

Concrete answers to these signal a clinic that has done the work; generic answers don’t reliably predict good outcomes. The difference shows up downstream in results, not in marketing materials.

The Fitzpatrick scale is a useful shorthand for a real physics fact about how melanin and ink compete for the same laser energy. Your self-assessed number gets you oriented for the conversation; your clinician’s assessment drives the actual protocol choices. The peer-reviewed evidence, especially for Fitzpatrick V and VI, is thinner than it should be, and an experienced operator with your skin type is worth more than any single device or device brand. A clinic that can name what they will do differently for your skin type, in specifics rather than reassurances, is a clinic worth a second consultation. That is the frame, and the questions above are how you test it.